ERBB2 and breast carcinoma: Conducting further research on the mechanism underlying miR-1246 and miR-155-induced trastuzumab resistance would facilitate the development of novel drugs that can be combined with trastuzumab to enhance treatment outcomes for HER2-positive breast cancer.